AbbVie (NYSE:ABBV) Releases FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 13.960-14.160 for the period, compared to the consensus EPS estimate of 14.560. The company issued revenue guidance of -. AbbVie also updated its Q1 2026 guidance to 2.560-2.600 EPS.

AbbVie Trading Up 0.3%

Shares of NYSE ABBV traded up $0.61 during mid-day trading on Thursday, reaching $212.20. The company had a trading volume of 992,419 shares, compared to its average volume of 7,181,494. The business’s 50-day moving average is $220.80 and its 200-day moving average is $224.19. The stock has a market cap of $375.21 billion, a price-to-earnings ratio of 90.05, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. AbbVie has a 52 week low of $164.96 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts forecast that AbbVie will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie’s dividend payout ratio is presently 293.22%.

Analysts Set New Price Targets

A number of research analysts have recently commented on ABBV shares. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Guggenheim restated a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. Piper Sandler upped their price target on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. UBS Group cut their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Finally, Citigroup cut their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $252.65.

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by corporate insiders.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie sued the U.S. government seeking to narrow which patients qualify for a federal drug‑discount program — a move aimed at limiting mandatory discounts and protecting revenue/margins if the court sides with AbbVie. This is the biggest near‑term corporate action likely viewed favorably by investors concerned about pricing erosion. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
• Positive Sentiment: New dermatology data presented for Skyrizi and Rinvoq (long‑term outcomes, safety and new indications data) could support continued sales momentum and broaden labels — reinforcing the company’s post‑Humira growth story that underpins guidance and cash generation. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: Dividend and cash‑flow narrative remains a tailwind: coverage highlights AbbVie’s high free cash flow, multi‑decade dividend streak and recent dividend raise — attractive to income investors and supportive of the stock’s defensive appeal. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Neutral Sentiment: BOTOX® Cosmetic community program and consumer/brand initiatives continue (PR), helpful for aesthetics franchise branding but unlikely to move near‑term fundamentals materially. BOTOX® Cosmetic Empowers Women Entrepreneurs
• Neutral Sentiment: Cantor Fitzgerald trimmed its price target modestly (from $250 to $240) but kept an overweight rating — suggests confidence in upside over time even as near‑term expectations are fine‑tuned. Benzinga note on Cantor Fitzgerald price target change
• Negative Sentiment: J&J’s Tremfya reclaimed the top spot in TV drug ad spending from AbbVie — fewer or lower consumer ad dollars for AbbVie could signal reduced promotional support for its brands or a strategic pullback, a potential headwind to near‑term demand growth. J&J’s Tremfya retakes TV drug ad spending crown from AbbVie
• Negative Sentiment: Participation in discount channels (e.g., Humira listed on TrumpRx at a steep discount) and political/program risks keep revenue exposure to pricing pressure top of mind for investors; the lawsuit seeks relief but regulatory/legal outcomes are uncertain. AbbVie Puts Humira on TrumpRx at Steep Discount
• Negative Sentiment: Analyst debate on valuation vs. pipeline growth persists — some coverage flags valuation doubts despite pipeline and operating leverage, which can cap near‑term upside until clarity on sustained product growth arrives. Why The AbbVie (ABBV) Story Is Shifting As Immunology Hopes Meet Valuation Doubts

Institutional Trading of AbbVie

A number of institutional investors have recently modified their holdings of the company. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter valued at approximately $28,000. Imprint Wealth LLC raised its position in shares of AbbVie by 56.3% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the last quarter. IFC & Insurance Marketing Inc. purchased a new position in shares of AbbVie in the 4th quarter valued at approximately $31,000. Quarry LP purchased a new position in shares of AbbVie in the 3rd quarter valued at approximately $41,000. Finally, Jessup Wealth Management Inc purchased a new position in shares of AbbVie in the 4th quarter valued at approximately $42,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.